A Study of LY3023414 in Japanese Participants With Advanced Cancer

NCT02536586 | Completed Phase 1

• 2 other identifiers: 15838I6A-JE-CBBH
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 2

Brief Summary

The main purpose of this study is to evaluate the tolerability of an investigational drug known as LY3023414 in Japanese participants with advanced cancer or cancer that has spread to another part(s) of the body. The study will also explore the safety of the drug. It will measure how much of the drug gets into the blood steam and how long the body takes to get rid of it. It will investigate anti-cancer activity.

Conditions

Neoplasm

Outcome Measures

Primary Outcomes (1)

• Number of Participants with LY3023414 Dose-Limiting Toxicities (DLT)

  Cycle 1 (21 days)

Secondary Outcomes (3)

• Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve (AUC) of LY3023414

  Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)

• Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3023414

  Predose Cycle 1 through predose Cycle 3. (Cycle = 21 days.)

• Proportion of Participants With Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])

  Baseline through study completion (estimated as up to five months)

Study Arms (1)

LY3023414

EXPERIMENTAL

LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.

Drug: LY3023414

Interventions

LY3023414 DRUG

LY3023414 administered orally.

LY3023414

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic and must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have failed or for whom standard therapy would not be appropriate.
• Have the presence of measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• Have adequate organ and coagulation function.
• Have discontinued all previous cancer therapies, and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 half-lives prior to study treatment, whichever is shorter, and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy for at least 42 days.
• Are able to swallow capsules.
• Males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug.
• Females with childbearing potential: Must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug.
• A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration.

You may not qualify if:

• Have serious pre-existing medical conditions.
• Have symptomatic central nervous system malignancy or metastasis.
• Have known acute or chronic leukemia or current hematologic malignancies that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
• Have a known active fungal, bacterial, and/or known viral infection.
• Intolerance to any previous treatment with any phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitor. Treatment with any PI3K/AKT/mTOR inhibitor must have discontinued for at least 21 days or 5 half-lives prior to first study drug administration, whichever is shorter, and participants must have recovered from the acute effects of therapy.
• Have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results.
• Participants with active alcohol abuse, as determined by the investigator.
• Have a history of heart failure according to New York Heart Association Class ≥3.
• Have corrected QT (QTc) interval of \>470 milliseconds (msec) on screening electrocardiogram (ECG).
• Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
• Have any evidence of clinically active interstitial lung disease (ILD).

Sponsors & Collaborators

• Eli Lilly and Company: lead

Study Sites (2)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

Chiba, 277 8577, Japan

Location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

Tokyo, 104-0045,, Japan

Location

MeSH Terms

Conditions

Neoplasms

Interventions

LY3023414

Study Officials

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

  Eli Lilly and Company

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2015
• First Posted: September 1, 2015
• Study Start: September 1, 2015
• Primary Completion: February 9, 2017
• Study Completion: February 9, 2017
• Last Updated: July 24, 2018

Record last verified: 2018-07

Locations

JP (2)